Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00266643 · ClinicalTrials.gov registry record · Phase 4
Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 205
- Enrollment target
NCT00266643: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00266643 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 205 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00266643, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 205 participants
- Enrollment target
Study Summary
This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.
Interventions
- DRUG duloxetine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
What the finished NCT00266643 record still lists
NCT00266643 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which duloxetine hydrochloride is the first listed.
NCT00266643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00266643 about?
NCT00266643 is a clinical study titled "Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain". This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.
What is the current status of trial NCT00266643?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 205 participants. The study started on 2005-12. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00266643?
The interventions under investigation include: duloxetine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00266643?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00266643's enrollment target sits among peer trials
205 402nd of 2000 higher than 1,599 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia